Paul Harrington, MD
Family Medicine · Charlton, MANPI 1972671758
Payments from drug & device makers
Across 423 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AstraZeneca$1K
- AbbVie$882
- Novo Nordisk$776
- Boehringer Ingelheim$487
- Amarin Pharma, Inc.$381
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,135100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 63 | $1,313 |
| AstraZeneca | 59 | $1,000 |
| AbbVie(2 entities) | 43 | $882 |
| Novo Nordisk | 41 | $776 |
| Boehringer Ingelheim | 26 | $487 |
| Amarin Pharma, Inc. | 21 | $381 |
| Pfizer | 18 | $335 |
| Amgen | 14 | $294 |
| GSK | 20 | $294 |
| Johnson & Johnson | 16 | $257 |
| Abbott | 12 | $248 |
| Exact Sciences | 9 | $246 |
| Ardelyx, Inc. | 9 | $208 |
| E.r. Squibb & Sons, L.L.C. | 8 | $166 |
| Novartis | 9 | $161 |
| Astellas Pharma US Inc | 5 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $120 |
| Phathom Pharmaceuticals, Inc. | 6 | $119 |
| Sanofi-aventis U.S. LLC | 4 | $91 |
| Esperion Therapeutics, Inc. | 3 | $76 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Bayer | 4 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Biohaven Pharmaceuticals, Inc. | 2 | $57 |
| Merck | 4 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $21 |
| Verona Pharma, Inc. | 1 | $20 |
| Almatica Pharma LLC | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$8,146 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 109 | $171,285 |
| OzempicSemaglutide | 153 | $165,107 |
| TrulicityDulaglutide | 140 | $160,050 |
| EliquisApixaban | 107 | $134,429 |
| FarxigaDapagliflozin Propanediol | 89 | $108,079 |
| XareltoRivaroxaban | 74 | $86,064 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $75,197 |
| MounjaroTirzepatide | 72 | $74,220 |
| TradjentaLinagliptin | 26 | $36,872 |
| JanuviaSitagliptin Phosphate | 22 | $28,180 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $26,133 |
| Bydureon BciseExenatide Microspheres | 30 | $26,051 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $18,716 |
| Atorvastatin Calcium | 1,169 | $15,937 |
| OxycontinOxycodone Hcl | 24 | $15,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,313 | $234,270212 claims |
| Boehringer IngelheimJardiance, Tradjenta | $487 | $208,157135 claims |
| Novo NordiskOzempic | $776 | $165,107153 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,000 | $139,690139 claims |
| PfizerEliquis | $335 | $134,429107 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $294 | $99,931145 claims |
| Johnson & JohnsonXarelto | $257 | $86,06474 claims |
| MerckJanuvia | $52 | $28,18022 claims |
| AbbVieLinzess, Synthroid | $882 | $9,44050 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Charlton
- Robert BeckWestford$2.1M
- Katherine Gergen BarnettBoston$226K
- Peter O'DwyerBoston$163K
- Kelly LannuttiWeymouth$122K
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.